Clinical Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suzuki, H.
Right arrow Articles by Finn, O. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, H.
Right arrow Articles by Finn, O. J.
Clinical Cancer Research Vol. 11, 1521-1526, February 2005
© 2005 American Association for Cancer Research

Cancer Therapy: Clinical

T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease

Hiroyuki Suzuki, Daniel F. Graziano, John McKolanis and Olivera J. Finn

Department of Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania

Requests for reprints: Olivera J. Finn, E1040 Biomedical Science Tower, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. Phone: 412-648-9816; Fax: 412-383-8859; E-mail: ojfinn{at}pitt.edu.


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Cyclin B1–derived peptides were shown by us to be targets of tumor-specific CD8+ T cells in patients with breast and head and neck cancer. We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell–dependent humoral immune responses in vivo in patients with different types of tumors.

Experimental Design: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody. We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking.

Results and Conclusions: Cyclin B1 elicits helper T cell–dependent antibody responses in vivo. Tumors with higher level of cyclin B1 expression elicit higher anti-cyclin B1 antibody levels. Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA. Cyclin B1–specific IgG was also detected in long-term smokers and in patients with preneoplastic lung disease. Immune responses to aberrantly expressed cyclin B1 in tumors and premalignant lesions should be further explored as diagnostic and prognostic markers, in addition to their immunotherapeutic potential.

Key Words: tumor antigen • cancer vaccine • cell cycle


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell division is a critical event in tumor progression and numerous molecules involved in this process have been the subject of intense investigation in tumor biology. Cyclins, molecules that control the progression through the cell cycle, have been shown to be overexpressed in various human cancers (1–6). Cyclin B1 is important in the cell cycle progression from G2-to-M phase (7). Correlation has been found between the extent of cyclin B1 overexpression in the primary tumor and clinical outcome for patients with cancer of the lung, esophagus, and tongue (8–12). We have a particular interest i cyclin B1 because we recently showed that cyclin B1 can serve as a tumor-specific antigen and that tumor-specific CTL derived from patients with breast and head and neck cancer recognize HLA-A2 presented peptides derived from overexpressed cyclin B1 protein (13). We furthermore showed that in addition to being overexpressed in tumors compared with normal proliferating cells, cyclin B1 is located in the cytoplasm rather than the nucleus, and this aberrant expression (overexpression and in the wrong location) is a result of p53 inactivation (14).

In this paper, we extend our published observations on cyclin B1 as a tumor antigen recognized by human cytotoxic T cells by studying in more detail its ability to elicit T cell–dependent humoral immune responses in patients with various types of tumors. Two previously published studies have shown that antibody against cyclin B1 can be found in patients with various tumors and might be a useful diagnostic marker in combination with antibodies against several other tumor antigens (15, 16). Focusing more closely on lung cancer, we show that antibody is present at both early and late stages of cancer, as well as in sera of heavy smokers that in their lungs have preneoplastic changes that overexpress cyclin B1.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patient Samples. Sera and tumor tissues from patients with breast, pancreatic, colon, and lung cancer were collected at the time of diagnosis, under the Institutional Review Board–approved protocol No. 93–34.

ELISA Assay. ELISAs for detecting anti-cyclin B1 antibody were done as previously described (17). Briefly, 50 µL of recombinant cyclin B1 protein (source and isolation procedure described below) at a concentration of 1 µg/mL in PBS were loaded into 96-well microtiter polystyrene base immunoassay plates (Dynex, Chantilly, VA), and incubated overnight at 4°C. Plates were washed with PBS and blocked with 2.5% bovine serum albumin in PBS for 1 hour. After washing, 50 µL of diluted serum were added and incubated for 1 hour at room temperature. Plates were washed with 0.1% Tween 20 in PBS, and the secondary antibody, ALP-labeled polyvalent goat anti-human IgM, IgG, and IgA (Sigma-Aldrich, St. Louis, MO) in 2.5% bovine serum albumin was added and plates incubated for 1 hour at room temperature. The plates were washed and filled with 100 µL per well of ALP substrate solution (Sigma-Aldrich). After 1 hour of incubation in the dark, the reaction was stopped with 50 µL of 0.5 mol/L NaOH and the absorbance at 405 nm was measured using the plate reader MRX Revelation (Thermo Labsystems, Chantilly, VA). The isotype of the anti-cyclin B1 antibody was determined using the same method described above except that isotype-specific ALP-labeled goat anti-human IgM, IgG, and IgA antibodies were used as secondary antibodies in the ELISA.

Recombinant cyclin B1 protein was obtained from two different sources. Insect cells infected with recombinant baculovirus expressing human cyclin B1 were purchased from BD PharMingen (San Diego, CA). The cell pellet was lysed with a lysis buffer consisting of 1% CHAPS (Sigma-Aldrich), 150 mmol/L NaCl, and 20 mmol/L Tris-Cl (pH 8.0) in the presence of protease inhibitors (Aprotinin, leupeptin, pepstatin phenylmethylsulfonyl fluoride, EDTA, and iodoacetamide). The lysate was centrifuged at 10,000 x g for 20 minutes and the supernatant was run over a column of protein G-Sepharose (Amersham Biosciences, Piscataway, NJ) before it was applied to an affinity column containing anti-cyclin B1 antibody (BD PharMingen) covalently coupled to protein G-Sepharose. Cyclin B1 was eluted from the column in 1 mL fractions using 0.1 mol/L triethylamine (pH 11.5) into a tube containing the same volume of 1 mol/L Tris (pH 6.7), to neutralize the pH. For further purification, ion exchange chromatography was done using a Rainin HPLC separation system (Varian, Woburn, MA). Either lysate or affinity column products were dialyzed into HEPES-buffered saline (10 mmol/L HEPES and 150 mmol/L NaCl) and applied to a Mono Q anion exchange column (Amersham Biosciences). Fractions were eluted with a 30-minute linear gradient of 150 to 500 mmol/L NaCl, at a flow rate of 1 mL/min. To identify column fractions that contained cyclin B1, samples were run on a 10% SDS gel and analyzed for purity by Coomassie blue staining and for specificity by Western blot. The preparation was highly pure as judged by the lack of detection of other protein bands on the gel. When purified recombinant protein became available through Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), that was expressed in Escherichia coli, samples of positive and negative sera were retested and results confirmed with this new commercial preparation.

Immunohistochemical Staining of Cyclin B1 in Tissue Sections. Formalin-fixed, paraffin-embedded tissues were sectioned (3-5 µm), air-dried overnight at 37°C, deparaffinized and dehydrated, and stained with the mouse anti-human cyclin B1 antibody, GNS-1 (BD PharMingen). The avidin-biotin peroxidase method was applied according to the manufacturer's instructions supplied with the Vecstatin ABC Elite staining kit (DAKO Co., Carpinteria, CA).

Statistical Analysis. A Student's t test was used to detect significant differences in the ELISA assays between absorbance values in the cancer patients' sera and healthy age-matched controls. Differences with P < 0.05 were considered significant.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Anti-Cyclin B1 Antibodies of Different Isotypes Are Present in Sera of Patients. Figure 1 shows ELISA results obtained on sera from 120 patients, 7 with breast cancer, 17 with pancreatic cancer, 27 with colon cancer, and 69 with lung cancer. The absorbance reading at 405 nm (A405) corresponds to the amount of specific antibody present in the serum. The A405 values of various sera ranged from 0.005 to 1.939. Values obtained with the sera from cancer patients were compared with values obtained on 27 healthy controls, 5 to 10 of which were included in every assay. To gain more insight into the similarity or differences between various cancer types and patients responses to cyclin B1, we divided all the antibody positive patients into "positive" (absorbance, 0.5000-0.999) and "strong positive" (absorbance, ≥1). Breast cancer patients were the best responders, 43% of the sera falling into the strong positive group, followed by colon cancer patients (22% strong positive) and pancreatic cancer patients (18% strong positive). The lowest level of antibody was found in lung cancer patients. We considered that this might be due to the stage of the disease at diagnosis, when the sera were collected. Among the lung cancer patients, we had 29 patients at stage I, 11 patients at stage II, 16 patients at stage III, and 4 patients at stage IV at the time of diagnosis. For nine patients, this information was not available. Figure 2A shows that there is no significant difference in antibody levels at different stages of disease. Antibody was found already at stage I, with a trend towards a slight increase with a more advanced stage II disease and then a slight decrease as the tumor progresses. In Fig. 2B, we show that both, non–small cell lung cancers as well as small cell lung cancers can elicit anti-cyclin B1 antibody responses.



View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1 Detection of anti-cyclin B1 antibodies in sera of cancer patients. Sera from cancer patients and healthy donor controls were tested for their reactivity to recombinant cyclin B1 protein using an ELISA assay. Single patient's serum ({bullet}). Absorbance at 405 nm. *, P < 0.05; **, P < 0.01 (all values from patients with cancer were significantly higher than those from healthy middle age donors).

 


View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2 Anti-cyclin B1 antibodies are present in different stages (A) and different types (B) of lung cancer. Sera from cancer patients taken at the time of diagnosis were tested for their reactivity to recombinant cyclin B1 protein using an ELISA assay. Absorbance at 405 nm. Stage of lung cancer at diagnosis (stages I-IV). NSCLC, Non–small cell lung cancer; small cell lung cancer; SCLC, small cell lung cancer.

 
We also compared antibody levels in sera from six lung cancer patients with recurrent (metastatic) disease with sera from 65 patients with primary disease (Fig. 3). With the caveat that the number of sera from recurrent disease is small, there seems to be a higher level of antibody present in these patients compared with patients sampled at the time of diagnosis of their primary tumors.



View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3 Higher anti-cyclin B1 antibody levels are found in recurrent (metastatic) lung cancer versus primary lung cancer. Sera from cancer patients taken at the time of diagnosis were tested for their reactivity to recombinant cyclin B1 protein using an ELISA assay. Absorbance at 405 nm.

 
We did antibody isotype analyses on three strong positive sera from each tumor type (Fig. 4). In patients with breast and colon cancer, the antibody response was primarily of the IgG isotype with low level or no IgM. In contrast, pancreatic cancer patients maintained significant levels of IgM and produced IgA antibody in addition to IgG. IgA isotype was seen in two lung cancer patients as well.



View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4 Presence of different anti-cyclin B1 antibody isotypes in patients' sera. Three sera from each tumor type, breast, colon, pancreatic, and lung, found to be strong positive for total immunoglobulin in ELISA, were tested in isotype-specific ELISA. % Total antibody of each isotype. Black bars, IgM; spotted bars, IgG; gray bars, IgA.

 
We were unable to obtain tumor sections from most of the patients whose sera we tested for the presence of anti-cyclin B1 antibody. However, in tumor sections that were available from four patients, there was a very good correlation between the level of cyclin B1 expression in tumor tissue (Fig. 5A) and the level of serum anti-cyclin B1 antibody (Fig. 5B).



View larger version (75K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5 Correlation of the level of cyclin B1 expression in the tumor and the level of serum antibody reactivity in ELISA. A, sections of metastatic lesions from two breast cancer patients and one colon cancer patient and the primary tumor from a pancreatic cancer patient were stained with anti-cyclin B1 antibody for the presence of cyclin B1 protein. Magnification 100x. B, sera from the same four patients were tested in ELISA for the presence of anti-cyclin B1 antibody. Absorbance at 405 nm. Column, mean value of triplicate wells; bars, ±SE.

 
Cyclin B1 Overexpression, Antibody Production, and Smoking. We also tested sera from 20 patients with benign lung disease (5 with granuloma, 6 with inflammatory diseases, 3 with benign tumors, 3 with interstitial lung disease, 2 with metaplasia, and 1 with dysplasia), divided into heavy smokers (n = 9; ≥40 pack-years) or light or nonsmokers (n = 11; <40 pack-years; Fig. 6A). The antibody level in the sera from heavy smokers was higher (absorbance, 0.469 ± 0.17) than in light smokers or nonsmokers (absorbance, 0.308 ± 0.128), and that difference was significant (P < 0.01). Immunohistochemical staining of sections of lung tissue from two heavy smokers, one diagnosed with a displastic lesion (patient 1) and the other with a metaplastic lesion (patient 2), showed that cyclin B1 protein was already overexpressed in both premalignant lesions to levels equal or higher to those seen in fully transformed cancer cells (Fig. 6B).



View larger version (69K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6 Anti-cyclin B1 antibody in patients with benign and premalignant lung disease and cyclin B1 overexpression in premalignant lesions. A, sera from 20 patients with benign lung disease were tested by ELISA. Patients were divided into two groups by smoking history (heavy smoker group, ≥40 pack-years; light or nonsmoker group, <40 pack-years). B, staining for cyclin B1 overexpression in bronchial metaplasia (patient 1) and dysplasia (patient 2). Top, at 40x original magnification; bottom, at 100x original magnification.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Cyclin B1 is an important molecule involved in the transition from G2-to-M phase of the normal cell cycle (7). It regulates cell division and cell arrest by cooperating with cdc2 kinase (18). The cyclin B1/cdc2 complex initiates chromosome condensation, destruction of nuclear membrane, and assembly of the mitotic spindle (19, 20). We and others have shown that cyclin B1 is overexpressed and mislocalized in the cytoplasm of many types of human cancers (4–6) and cancer cell lines (21). Kushner et al. showed that the level of cyclin B1 expression can correlate with staging of head and neck cancer (21), and a correlation between cyclin B1 overexpression and the proliferation marker Ki-67 has also been shown (10). Furthermore, it was reported that the level of expression of cyclin B1 can be correlated with disease prognosis in patients with lung, tongue, and esophageal cancer (10–12). Therefore, the deregulated expression of cyclin B1 seen in many cancers may be linked to carcinogenesis and tumor progression (22).

Recently, we discovered that aberrantly expressed cyclin B1 is recognized by human T cells as a tumor-specific antigen and that patients with breast and head and neck cancer have circulating CD8+ T cells specific for various peptides derived from this molecule. In the current study, we sought to determine if there were also specific antibody responses in patients with tumors known to overexpress cyclin B1. We found that cyclin B1 elicits helper T cell–dependent antibodies as evidenced by high frequency of isotype switching, indirectly demonstrating that in addition to previously detected cyclin B1–specific CTL, helper T cells can also be generated that are specific for this antigen and functional in providing help to B cells.

Whereas the differences in antibody levels and isotypes found in patients with different tumor types are not statistically significant, we nevertheless found them informative. For example, we find in general higher level of antibody in recurrent (metastatic) disease than in nonrecurrent disease. This may be related to our observation that metastatic cells express the highest levels of cyclin B11 and thus provide the highest level of antigen. Most of the sera we tested from breast, pancreatic and colon cancer patients were derived in the setting of recurrent disease. The sera from lung cancer patients were primarily derived at the time of diagnosis of the primary disease, the majority being stages I and II.

We also found less isotype switching and highest levels of IgM in patients with pancreatic and colon cancer. This may be a direct result of the profound T-cell suppression in these two tumor types that we and others have published on before (23, 24) . In the absence of optimally functioning helper T cells, isotype switching would be expected to proceed at a much slower rate. In pancreatic and lung cancer patients, we also found IgA antibody. Pancreatic, lung, and other cancers produce transforming growth factor-ß (24, 25) that is known to be the cytokine that induces isotype switching to IgA (26). Thus, whereas cyclin B1–specific helper T cells promote the switch from cyclin B1 IgM to IgG, switching to IgA may be also due to tumor-produced transforming growth factor-ß.

Data presented here, showing that aberrantly expressed cyclin B1 can elicit T cell–dependent antibody responses, confirming and extending the previously published data by Koziol et al. (16), together with our previously published data on cyclin B1 specific human cytotoxic T-cell responses (13), validate the designation of this otherwise normal cell cycle regulatory protein as a tumor antigen.

Our finding that aberrant expression of cyclin B1 characterizes not only primary tumors but also metastatic tumors and premalignant lesions, suggests that it may be a good candidate antigen for cancer vaccines intended to prevent cancer recurrence or progression from premalignant disease to cancer. Detection of anti-cyclin B1 antibodies in long-term smokers and overexpression of this antigen in premalignant lesions, suggests that anti-cyclin B1 antibody may also serve as a serum marker for premalignant disease or for early detection of cancer.


   ACKNOWLEDGMENTS
 
We thank Dr. Jill Siegfried, Autumn Gaither Davis and the members of the University of Pittsburgh Cancer Institute Clinical Investigations Program for serum and tissue samples and helpful scientific input, and Dr. Sydney Finkelstein for help with immunohistology.


   FOOTNOTES
 
Grant support: National Cancer Institute Lung Cancer Specialized Programs of Research Excellence grant P50 CA 090440.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: H. Suzuki is currently at Department of Surgery I, Fukushima Medical University, Fukushima, Japan.

1 Yu and Finn, unpublished. Back

Received 3/17/04; revised 11/ 9/04; accepted 11/11/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Mckay JA, Douglas JJ, Ross VG, et al. Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res 2000;6:1113–8.[Abstract/Free Full Text]
  2. Bai M, Vlachonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 2001;14:1105–13.[CrossRef][Medline]
  3. Milde-Langosch K, Bamberger AM, Goemann C, et al. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001;127:537–44.[CrossRef][Medline]
  4. Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 1994;54:4285–8.[Abstract/Free Full Text]
  5. Kawamoto H, Koizumi H, Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant breast lesions. Am J Pathol 1997;150:15–23.[Abstract]
  6. Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol 1997;123:124–7.[CrossRef][Medline]
  7. Pines J, Hunter T. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature 1990;346:760–3.[CrossRef][Medline]
  8. Geddert H, Heep HJ, Gabbert HE, Sarbia M. Expression of cyclin B1 in the metaplasia-dysplasia carcinoma sequence of Barrett esophagus. Cancer 2002;94:212–8.[CrossRef][Medline]
  9. Milde-Langosch K, Bamberger A, Goemann C, et al. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001;127:537–44.
  10. Soria J, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60:4000–4.[Abstract/Free Full Text]
  11. Nozoe T, Korenaga D, Kobayashi A, Ohga T, Saeki H, Sugimachi K. Significance of cyclin B1 expression as an independent prognositic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002;8:817–22.[Abstract/Free Full Text]
  12. Hassan KA, El-Naggar AK, Soria J, Liu D, Hong WK, Mao L. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin Cancer Res 2001;7:2458–62.[Abstract/Free Full Text]
  13. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001;194:1313–23.[Abstract/Free Full Text]
  14. Yu M, Zhan Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002;1100:1–7.
  15. Covini G, Chan KLE, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997;25:75–80.[CrossRef][Medline]
  16. Koziol JA, Zhang J-Y, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120–6.[Abstract/Free Full Text]
  17. Kotera Y, Fontenot D, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856–60.[Abstract/Free Full Text]
  18. Pines J, Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989;58:833–46.[CrossRef][Medline]
  19. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications of in cell cycle control and cancer. Crit Rev Eukaryot Gene Exp 1995;5:127–56.[Medline]
  20. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992;61:441–70.[CrossRef][Medline]
  21. Kushner J, Bradley G, Young B, Jordan RC. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J Oral Pathol Med 1999;28:77–81.[Medline]
  22. Keyomarsi K, Pordec AB. Redundant cyclin overexpressions and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112–6.[Abstract/Free Full Text]
  23. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756–60.[Abstract/Free Full Text]
  24. von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001;7:925–32s.
  25. Kong F, Washington MK, Jirtle RL, Anscher MA. Plasma transforming growth factor-ß1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996;16:47–59.[CrossRef][Medline]
  26. Kim PH, Kagnoff MF. Transforming growth factor ß1 increases IgA isotype switching at the clonal level. J Immunol 1990;145:3773–8.[Abstract]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. Kondo, B. Maecker, M. R. Weihrauch, C. Wickenhauser, W. Zeng, L. M. Nadler, J. L. Schultze, and M. S. von Bergwelt-Baildon
Cyclin D1-Specific Cytotoxic T Lymphocytes Are Present in the Repertoire of Cancer Patients: Implications for Cancer Immunotherapy
Clin. Cancer Res., October 15, 2008; 14(20): 6574 - 6579.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. J. Finn
Immunological Weapons Acquired Early in Life Win Battles with Cancer Late in Life
J. Immunol., August 1, 2008; 181(3): 1589 - 1592.
[Full Text] [PDF]

Home page
 NEJMHome page
O. J. Finn
Cancer Immunology
N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715.
[Full Text] [PDF]

Home page
 JEMHome page
R. Spisek, A. Kukreja, L.-C. Chen, P. Matthews, A. Mazumder, D. Vesole, S. Jagannath, H. A. Zebroski, A. J.G. Simpson, G. Ritter, et al.
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy
J. Exp. Med., April 16, 2007; 204(4): 831 - 840.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Egloff, L. A. Vella, and O. J. Finn
Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer
Cancer Res., January 1, 2006; 66(1): 6 - 9.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E.M. Tan, J. A. Koziol, Y. Kida, M. A. Thorat, R. A. Badwe, B. Rocco, B. Djavan, O. de Cobelli, X. Wang, D. Ghosh, et al.
Autoantibodies in prostate cancer.
N. Engl. J. Med., December 29, 2005; 353(26): 2815 - 2817.
[Full Text] [PDF]

Home page
 NEJMHome page
O. J. Finn
Immune Response as a Biomarker for Cancer Detection and a Lot More
N. Engl. J. Med., September 22, 2005; 353(12): 1288 - 1290.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suzuki, H.
Right arrow Articles by Finn, O. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, H.
Right arrow Articles by Finn, O. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online